EDGAR·FLOW

InMed Pharmaceuticals Inc. — Form 8-K

Filed November 5, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 78/100
What the filing says
InMed Pharmaceuticals shareholders approved on November 4, 2026: (1) corporate name change to Mentari Therapeutics, Inc.; (2) a 10:1 share consolidation reducing outstanding shares from 5,493,735 to ~549,374; (3) a merger with Mentari Therapeutics (Delaware) whereby InMed shareholders will receive issuance of >20% new common shares plus contingent value rights (CVRs) tied to future milestone events; and (4) redomestication from British Columbia to Nevada. Voting showed strong shareholder support (88–97% approval across major proposals). The merger is pending satisfaction of closing conditions.
Why this rating

Merger + rebranding + 10:1 consolidation materially restructure the company and will substantially dilute current shareholders via >20% issuance. Relative to $3M market cap, this is transformational. However, filing contains no deal value, Mentari financial profile, or specifics of CVR payments, making full impact assessment impossible. Neutral impact: restructuring is neither clearly value-accretive nor destructive without more detail.

Price action (we called it neutral)
at our read · unknown
$1.75
+10 min · unknown
$1.75 ▲ 0.00%
+30 min · unknown
$14.99 ▲ 756.57%
+1 hr · unknown
$14.54 ▲ 730.91%
+4 hrs · unknown
$13.40 ▲ 665.49%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ INM · stock on Yahoo Finance ↗

See more from November 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.